With 1.12 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.36 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.6 whereas the lowest price it dropped to was $1.07. The 52-week range on RDHL shows that it touched its highest point at $8.75 and its lowest point at $1.06 during that stretch. It currently has a 1-year price target of $1000.00. Beta for the stock currently stands at 4.81.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RDHL was down-trending over the past week, with a drop of -29.41%, but this was down by -45.73% over a month. Three-month performance dropped to -12.20% while six-month performance fell -44.04%. The stock lost -82.61% in the past year, while it has lost -86.89% so far this year.
Float and Shares Shorts:
At present, 3.33 million RDHL shares are outstanding with a float of 2.96 million shares on hand for trading. On 2025-10-15, short shares totaled 29866.0, which was 89.99999999999999 higher than short shares on 1757894400. In addition to Mr. Dror Ben-Asher as the firm’s Co-Founder, Chairman & CEO, Mr. Razi Ingber serves as its Chief Financial Officer.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$40 being high and -$40 being low. For RDHL, this leads to a yearly average estimate of -$40. The surprise factor in the prior quarter was -$10.
